Medtronic Joins Mitral Valve Race in $458 Million Device Deal

Medtronic Plc will spend as much as $458 million to buy Twelve Inc., becoming the latest medical-device giant to buy an experimental product to replace the heart’s mitral valve without open-heart surgery.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.